A 26-year-old primigravid patient, at 11 weeks of gestation, was referred to the digestive surgery department for acute pancreatitis, the abdominal ultrasound revealed a solid pancreatic mass. The MRI showed a well circumscribed tumor in the body of the pancreas with no local or distant invasion. The diagnosis of solid pseudopapillary tumor of the pancreas (SPTP) was then suspected.After multi-disciplinary reunion including the patient and her husband, the decision was to operate the patient but first medically interrupt the pregnancy. The operation consisted in left pancreatectomy with conservation of the spleen gland. The histopathological examination confirmed the diagnosis of SPTP. There was no complication or recurrence after 10 months of follow up.
12022 Background: Methotrexate (MTX) is a mainstay in the treatment of ostosarcoma. MTX is characterized by a narrow therapeutic window, combined with high intra- and inter-patient variabilities. In our institute, safe administration of high dose MTX is ensured by using bayesian, adaptive dosing with feedback strategy. In patients with osteosarcoma, up to 20g/patient MTX is administred following an 8h infusion. From the 6th hour, the dose is tailored according to individual pharmacokinetics parameters, determined in real-time from two early sampling times (T3.5, T4.5) and a reference population. This method enables accurate adjustment of most patients around a target Cend of 10−3 M/L. Still, 15–20% of the patients show reduced MTX elimination rate, thus leading to an overlasting hospitalization time with folate rescue required to prevent severe toxicities. In this work, we studied the relevance of clinical or pareaclinical covariates likely to be associated with the MTX clearance so as to identify patients at risk of impaired elimination with subsequent increase in iatrogeny. Methods: This retrospective study was performed on 49 patients treated with HD-MTX. Population PK parameters were computed using Apis and NonMem routines. The second objective was to predict for how long MTX plasma concentration would remain above 0.2 μM/L, the threshold associated with toxicity, upper which folinic acid is required. Finally, simplified sampling strategy for folate rescue protocol was developed. Results: two covariates (creatinemia and ALAT) have been identified as being correlated with MTX clearance. Besides, simulation of the 0.2μM/L threshold reaching showed that it was possible to predict accurately the time most patients can leave the hospital safely. This, would have led to reduce the hospitalization stay by at least one day in 25% of the patients, thus optimizing their life quality while being cost-effective. Conclusions: in this study, we showed that high dose MTX can be administred safely using an adaptive dosing with drug monitoring strategy. Besides, modelling of MTX PK parameters leads to an accurate estimation of the elimination pattern of this drug, thus enabling a planification of the time patients leave the hospital. No significant financial relationships to disclose.
A 37-year-old primigravid patient, at 20 weeks of gestation, was referred to gynecology and obstetrics department for pelvic pain and vaginal bleeding. At speculum examination, she had a cervical bleeding mass. The transvaginal ultrasound showed a complex left pelvic masses. A pelvic MRI was performed, revealing an extended cervical cancer with lymph node metastasis. The patient was diagnosed with an invasive locally advanced tumor of the cervix. After multi-disciplinary reunion, pregnancy was interrupted, and the patient had hysterectomy, adnexectomy and lymphadenectomy associated with adjuvant chemotherapy. The early follow up did not reveal any complication.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.